Evidence map›Paper›PMID 26898686›Full record

ReviewCurrent neurology and neuroscience reports2016

Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease.

Yasaman Kianirad, Tanya Simuni

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Article
  3. Phosphoramidate derivates as controlled-release prodrugs of l-Dopa.Bioorganic & medicinal chemistry letters · 2019
    Article
  4. Observational
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yasaman KianiradDepartment of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. Yasaman.Kianirad@northwestern.edu.
Tanya SimuniParkinson's Disease and Movement Disorders Center, Department of Neurology, Feinberg School of Medicine, Northwestern University, Abbott Hall 11th Floor, 710 North Lake Shore Drive, Chicago, IL, 60611, USA. TSimuni@nm.org.
Northwestern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Levodopa (LD) is the most effective medication to treat Parkinson's disease (PD). However, motor fluctuations and drug-induced dyskinesia compromise the long-term success of levodopa therapy in PD. These response complications are due, at least in part, to fluctuating LD plasma levels (as a result of erratic gastric emptying, variable jejunal absorption, and most importantly, the short half-life of LD) with standard levodopa formulations. Keeping levodopa concentrations as constant as possible is the target for improving the pharmacokinetics and developing new ways of LD administration. In this article, we review novel oral and non-oral LD formulations including the ones that have successfully completed phase 3 clinical trials and have come to market and ones that are still in earlier phases of clinical development.

Indexed as

AnimalsAntiparkinson AgentsDrug Delivery SystemsHumansLevodopaParkinson DiseaseAntiparkinson AgentsLevodopaExtended-release formulationGastroretentionIntrapulmonary deliveryLevodopa infusionsParkinson’s diseaseSubcutaneous delivery

Identifiers

PMID26898686
OpenAlexW2282362772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.